News
CPMV
0.530
NaN%
--
Mosaic ImmunoEngineering Delays 10-Q Filing
TipRanks · 11/12 22:49
Weekly Report: what happened at CPMV last week (0908-0912)?
Weekly Report · 09/15 10:19
Weekly Report: what happened at CPMV last week (0901-0905)?
Weekly Report · 09/08 10:21
Weekly Report: what happened at CPMV last week (0825-0829)?
Weekly Report · 09/01 10:17
Weekly Report: what happened at CPMV last week (0818-0822)?
Weekly Report · 08/25 10:24
Weekly Report: what happened at CPMV last week (0811-0815)?
Weekly Report · 08/18 10:19
Mosaic ImmunoEngineering Delays 10-Q Filing
TipRanks · 08/12 22:17
Weekly Report: what happened at CPMV last week (0804-0808)?
Weekly Report · 08/11 10:23
Weekly Report: what happened at CPMV last week (0728-0801)?
Weekly Report · 08/04 10:25
Weekly Report: what happened at CPMV last week (0721-0725)?
Weekly Report · 07/28 10:26
Weekly Report: what happened at CPMV last week (0714-0718)?
Weekly Report · 07/21 10:19
Weekly Report: what happened at CPMV last week (0707-0711)?
Weekly Report · 07/14 10:24
Weekly Report: what happened at CPMV last week (0630-0704)?
Weekly Report · 07/07 10:20
Weekly Report: what happened at CPMV last week (0623-0627)?
Weekly Report · 06/30 10:23
Weekly Report: what happened at CPMV last week (0616-0620)?
Weekly Report · 06/23 10:19
Weekly Report: what happened at CPMV last week (0609-0613)?
Weekly Report · 06/16 10:23
Weekly Report: what happened at CPMV last week (0602-0606)?
Weekly Report · 06/09 10:24
Weekly Report: what happened at CPMV last week (0526-0530)?
Weekly Report · 06/02 10:29
Weekly Report: what happened at CPMV last week (0519-0523)?
Weekly Report · 05/26 10:28
Weekly Report: what happened at CPMV last week (0512-0516)?
Weekly Report · 05/19 10:23
More
Webull provides a variety of real-time CPMV stock news. You can receive the latest news about Mosaic Immunoengineering Inc through multiple platforms. This information may help you make smarter investment decisions.
About CPMV
Mosaic ImmunoEngineering, Inc. is a development-stage biotechnology company focused on advancing and eventually commercializing immunotherapies for the treatment of cancer. The Company is focused on new product candidates and platforms to expand its pipeline based on a deep understanding of immunotherapies and its license agreements with University of California San Diego.